Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer

Date
2012
Author
Demir, G.
Seber, S.
Korkmaz, T.
Aydin, K.
Bozkurt, M.
Akun, E.
Tecimer, C.
Okutur, K.
Hasbal, B.
Namal, E.
Metadata
Show full item record
Abstract
Purpose: To determine the clinical features of bevacizumab-associated toxicities in metastatic colorectal cancer (MCRC) patients.
URI
http://hdl.handle.net/20.500.12627/27989
Collections